Compare Morgan Stanley (MS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Pfizer Inc — how do they compare? Morgan Stanley trades at $189.05 (market cap $294.39B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Morgan Stanley is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 93 Days and Pfizer Inc for 158 Days on average.
| MS | PFE | |
|---|---|---|
Market Cap | $294.39B | $158.56B |
Volume | 5,836,423 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $228.42 | $29.02 |
52-Week Low | $151.86 | $23.67 |
Typical Hold Time | 93 Days | 158 Days |
Enterprise Value | $660.04B | $210.06B |
Dividend Yield | 2.45% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.
The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
